Canakinumab
A monoclonal antibody that blocks interleukin-1 beta, a key mediator of inflammation, used to treat rare autoinflammatory diseases such as systemic juvenile idiopathic arthritis, Still's disease, and certain periodic fever syndromes. It provides targeted immunosuppression without broadly suppressing the immune system. It is given by subcutaneous injection every few weeks to months.
Áreas Terapêuticas
Mecanismo de Ação
Binds to a specific target antigen on tumor cells or immune cells, triggering immune-mediated destruction through antibody-dependent cellular cytotoxicity (ADCC), complement-dependent cytotoxicity (CDC), or direct signaling inhibition.
Pharmacokinetics (PK)
Pharmacodynamics (PD)
Binds to a specific target antigen on tumor cells or immune cells, triggering immune-mediated destruction through antibody-dependent cellular cytotoxicity (ADCC), complement-dependent cytotoxicity (CDC), or direct signaling inhibition.
HBD / HBA
- / -
No targets recorded
Target interaction data is not yet available for this drug.
No interactions recorded
Drug interaction data is not yet available for this compound.
No side effects recorded
Side effect data is not yet available for this drug.
Perguntas frequentes
A monoclonal antibody that blocks interleukin-1 beta, a key mediator of inflammation, used to treat rare autoinflammatory diseases such as systemic juvenile idiopathic arthritis, Still's disease, and certain periodic fever syndromes. It provides targeted immunosuppression without broadly suppressing the immune system. It is given by subcutaneous injection every few weeks to months.
Binds to a specific target antigen on tumor cells or immune cells, triggering immune-mediated destruction through antibody-dependent cellular cytotoxicity (ADCC), complement-dependent cytotoxicity (CDC), or direct signaling inhibition.
Yes, Canakinumab is an approved drug. It has reached clinical phase 4. It is classified as a Antibody.
References & Data Sources
- ChEMBL — European Bioinformatics Institute (EBI). CHEMBL1201834. Open-access bioactivity database.
Data aggregated from publicly available pharmacological databases. Last updated 2026-02-27.
Embed This Widget
Add the script tag and a data attribute to embed this widget.
<script src="https://cdn.jsdelivr.net/npm/drugfyi-embed@1/dist/embed.min.js" defer></script>
<div data-drugfyi="drug" data-slug="canakinumab"></div>Embed via iframe for maximum compatibility.
<iframe src="https://drugfyi.com/iframe/drug/canakinumab/" width="420" height="400" frameborder="0" style="border:0;border-radius:10px;max-width:100%" loading="lazy"></iframe>Paste this URL in WordPress, Medium, or any oEmbed-compatible platform.
https://drugfyi.com/drug/canakinumab/Add a dynamic SVG badge to your README or docs.
[](https://drugfyi.com/drug/canakinumab/)Use the native HTML custom element.
<script src="https://cdn.jsdelivr.net/npm/drugfyi-embed@1/dist/embed.min.js" defer></script>
<drugfyi-drug slug="canakinumab"></drugfyi-drug>